1-3 of 3
Nina D. Wagner-Johnston
Close
Sort by
Journal Articles

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Clinical Trials & Observations
Rakesh Awasthi, Lida Pacaud, Edward Waldron, Constantine S. Tam, Ulrich Jäger, Peter Borchmann, Samantha Jaglowski, Stephen Ronan Foley, Koen van Besien, Nina D. Wagner-Johnston, Marie José Kersten, Stephen J. Schuster, Gilles Salles, Richard T. Maziarz, Özlem Anak, Christopher del Corral, Jufen Chu, Irina Gershgorin, Iulian Pruteanu-Malinici, Abhijit Chakraborty, Karen Thudium Mueller, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2020) 4 (3): 560–572.
https://doi.org/10.1182/bloodadvances.2019000525
Published: 2020
Includes: Supplemental data
Journal Articles

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Laura K. Schoch, Kenneth R. Cooke, Nina D. Wagner-Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2226–2229.
https://doi.org/10.1182/bloodadvances.2018019208
Published: 2018
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data